GlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
BARCELONA - GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
AstraZeneca and its U.S. development partner Merck & Co said their Lynparza drug cut the risk of the cancer progressing again by 41%. The figure was 38% for GSK’s drug. But different trial settings will make it difficult to predict how physicians will weigh up the two drugs. Both companies, which are competing to burnish their oncology credentials, showed that not just the small group of women with mutated BRCA genes can benefit as the results also covered the full variety of ovarian cancer.
But in a patient subgroup with tumours where the DNA repair was still intact, GSK appears to make headway over its rivals. “We know now we can use PARP inhibitors in the first-line setting beyond women with BRCA mutations,” said Susana Banerjee, an oncologist at the Royal Marsden NHS Foundation Trust in London, who discussed the results at an ESMO press conference.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
AstraZeneca, Merck ovarian cancer treatment improves progression-free survivalAstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diag...
Consulte Mais informação »
Ovarian cancer | Womenshealth.govAbout 1 in 60 women in the United States will develop ovariancancer. Here’s what you should know:
Consulte Mais informação »
CVS, Walgreens stop selling heartburn medicine Zantac due to safety concernsCVS and Walgreens suspend sales of the heartburn drug Zantac following a Food and Drug Administration alert that the medicine may contain a possible carcinogen.
Consulte Mais informação »
'Revolutionary' drug for prostate cancerOlaparib could be a 'transformative' treatment for thousands of men with advanced prostate cancer, say experts.
Consulte Mais informação »